Abbott Laboratories (ABT) stock
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/3049% above fair value
$108.52+1.27 (+1.18%)
Close on Nov 13, 2026Market cap $187.78BP/E 40.2Yield 2.21%
Abbott Laboratories enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Abbott Laboratories's enterprise value was $218.48B on Nov 11, 2026, against $230.81B a year earlier. Over the last 5 years it ranged from $163.33B to $260.99B, with a median of $205.85B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $218.48B | -2.7% |
| 2025 | Dec 31, 2025 | $224.50B | +9.4% |
| 2024 | Dec 31, 2024 | $205.20B | +1.9% |
| 2023 | Dec 29, 2023 | $201.39B | +0.1% |
| 2022 | Dec 30, 2022 | $201.20B | -22.9% |
| 2021 | Dec 31, 2021 | $260.99B | +24.7% |
| 2020 | Dec 31, 2020 | $209.35B | +23.5% |
| 2019 | Dec 31, 2019 | $169.49B | +17.8% |
| 2018 | Dec 31, 2018 | $143.92B | +32.1% |
| 2017 | Dec 29, 2017 | $108.92B | +78.2% |
| 2016 | Dec 30, 2016 | $61.13B | -12.9% |
| 2015 | Dec 31, 2015 | $70.22B | -3.5% |
| 2014 | Dec 31, 2014 | $72.76B | +20.6% |
| 2013 | Dec 31, 2013 | $60.35B | -44.5% |
| 2012 | Dec 31, 2012 | $108.81B | +12.6% |
| 2011 | Dec 30, 2011 | $96.68B | +8.0% |
| 2010 | Dec 31, 2010 | $89.53B | -1.6% |
| 2009 | Dec 31, 2009 | $91.00B | – |
See a number that looks wrong?